Abstracts

699 – Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in the Trio Cohort

Background Fostemsavir [FTR] is approved for use with other active antiretrovirals [ARVs] for treatment of heavily treatment-experienced people with HIV [PWH] and multi-drug resistance [MDR]. We described characteristics and treatment outcomes among PWH prescribed FTR in a real-world setting in the US.  Methods PWH initiating FTR from July 2020 (FDA approval) to June 2023 identified…

708 – A Strategy for Durable AAV-Vectored bNAb Expression in Adult Rhesus Macaques

Background Sustained expression of adeno-associated virus (AAV)-vectored anti-HIV-1 broadly neutralizing antibodies (bNAbs) could prevent and treat HIV-1 infection. However, durable expression of AAV-vectored bNAbs in vivo is limited by host immune responses, impeding efficacy studies in preclinical nonhuman primate (NHP) models. Programmed cell death protein (PD)-1 is an immune checkpoint protein on T cells that…

692 – A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations

Background Large randomized clinical trials of investigational agents in people with HIV (PWH) routinely exclude participants with adherence challenges. ACTG 5359, a phase III, prospective, randomized, open-label trial comparing long acting cabotegravir + rilpivirine (LAI) vs. oral standard of care (SOC) ART in PWH with a history of suboptimal adherence (persistent HIV-1 RNA >200 c/mL…

674 – Long-Term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort

Background Cabotegravir + rilpivirine long-acting (CAB+RPV LA) injectable was FDA approved for treatment experienced, suppressed (viral load [VL] <50 c/mL) people with HIV (PWH) on a monthly (Q1M; 2021) or every 2 months (Q2M; 2022) schedule. We assessed CAB+RPV LA use in a real-world setting over its first 3 years of availability. Methods Suppressed adults with HIV…

684 – What Do Early Adopters of Long-Acting Injectable Cabotegravir/Rilpivirine Think About It?

Background Little is known about experiences with long-acting injectable cabotegravir/rilpivirine (LA-CAB/RPV) in underserved people with HIV (PWH), particularly PWH initiating with viremia due to adherence challenges. Methods In a cross-sectional survey of PWH with ≥3 injections at Ward 86 (San Francisco), Grady Ponce de Leon (Atlanta), and the University of Chicago, we assessed treatment satisfaction…

669 – 24-Month Outcomes on Second-Line Antiretroviral Therapy in South Africa: A Target Trial Emulation

Background The WHO recommends dolutegravir (DTG) instead of ritonavir-boosted lopinavir (LPV/r) in second-line antiretroviral therapy (ART), and recycled tenofovir disoproxil fumarate (TDF)/emtricitabine or lamivudine (XTC) instead of zidovudine (AZT)/XTC as backbone. However, there is little long-term data from routine, low-resource settings, where DTG resistance may be emerging. We compared 24-month outcomes with these 3 regimens.…

718 – Synergistic Effect of NMV/r and Acquired Immunity in Reducing Severe COVID-19

Background Both immunization and nirmatrelvir-ritonavir treatment (NMV-r) are known to lower the risk of severe COVID-19 including hospitalization or death.  However, it is unclear whether the effect of NMV-r and acquired immunity (via vaccination or prior viral exposure indicated as serologic positivity) are additive or synergistic. Methods Non-hospitalized symptomatic adults infected with COVID-19 were enrolled into…

707 – Identification and Characterization of Novel Chemical Scaffolds With Anti-HIV Activities

Background HIV-1 protease (PR) is initially synthesized as part of the Gag-Pol polyprotein precursor, which undergoes regulated autoprocessing to produce free mature PR, essential for viral particle maturation and infectivity. We previously demonstrated that precursors and mature PRs have distinct enzymatic properties, as precursors are up to 1,000-fold less-sensitive to protease inhibitors (PIs) compared to…

706 – Development of a 2-Drug Long-Acting Removable Formulation for HIV Suppression

Background Non-adherence to HIV treatment increases the risk of viral rebound and the development of drug resistance. Long-acting formulations have shown improved compliance compared with conventional regimens requiring frequent dosing, leading to better outcomes and treatment continuation. Here, an in situ forming implant system (ISFI) was used to develop a long-acting (LA) formulation that can co-deliver two drugs…